NVO’s Ozempic Outshines LLY’s Mounjaro in Lowering Cardiovascular Risk
Novo NVO announced new real-world data from the COMPETE SWITCH Cardiovascular (CV) study comparing treatment strategies in adults…
Novo Nordisk provides update on the ZEUS phase 3 trial in people with ASCVD, CKD and inflammation
Novo Nordisk A/S Bagsværd, Denmark, 31 July 2026 – Novo Nordisk today announced headline results from the ZEUS cardiovascular…
COVID Vaccine Linked to New Side Effect, Especially in Older Adults
Older adults who received the latest COVID-19 vaccine were significantly less likely to suffer serious heart-related complications, according…
The 4.5 minute exercise that could slash your risk of a heart attack
Remarkably small daily adjustments to sleep, exercise, and diet could significantly lower the risk of heart attacks, a…
Scientists Just Discovered a Surprising Health Risk of a High-Protein Diet
Reviewed by Dietitian Emily Lachtrupp, M.S., RD Design elements: Getty Images. EatingWell design. Key Points A new study…
Wegovy® approved by FDA for the treatment of adults with noncirrhotic MASH with moderate to advanced liver fibrosis
“Today’s decision by the FDA reflects the continued progress in how we understand and treat patients with MASH,…